Pattern Pharma is a life sciences company
focused on harnessing the innate immune system
to combat cancer and infectious disease
About us
P2PAR: Our Lead Product
Pattern’s lead product, P2PAR, is an immunotherapeutic which activates innate immune cells to kill cancer cells and safely activate an efficacious innate and adaptive immune response, thereby overcoming the limitations of many traditional therapies.
Pattern’s P2PAR therapeutic is an improved, proprietary pharmaceutical-grade formulation of a safe and effective first-generation product.
P2PAR has high molar activity (a human dose is 3μg), is easy to store and use, and is effective when administered systemically (subcutaneously, intramuscularly, intravenously or intranasally) or intralesionally.
Pattern is about to enter a first-in-human clinical trial addressing a specific neoplasia caused by Human Papilloma Virus (HPV). In this context, Pattern plans to initiate a Phase 1/2 clinical trial in Q2 2021 at Massachusetts General Hospital.
P2PAR: How it works
P2PAR is an agonist of TLR1, TLR2, TLR4 and TLR6, and it specifically activates key innate immune cells including macrophages, dendritic cells (DCs) and natural killer cells.
In addition, P2PAR also mobilizes the adaptive immune system (via DCs) and creates protective immune memory through a process of in situ vaccination. This process occurs without any need to previously identify and isolate antigens or genetic material.
P2PAR triggers the transient production of Type I and II interferons and cytokines including chemokines by immune cells (TNFα, IL-12, IFN-β, IFN-γ, IL-1α, IL-1β, GM-CSF, MCP-1, IL-27, etc.). P2PAR also causes the membrane expression of costimulatory molecules (CD80, CD86, CD40) and MHCI and MHCII molecules on antigen-presenting cells, as well as the production of effector mediators such as nitric oxide and peroxynitrite.
Opportunities: Pipeline In A Product
Pattern has a pipeline of P2PAR opportunities based on strong supporting evidence of its safety and therapeutic efficacy in a range of indications, coming from clinical data from the first-generation product.
Our lead indication is a specific neoplasia caused by Human Papilloma Virus (HPV) and is a precursor to squamous cell carcinoma. Pattern is leveraging five third-party HPV clinical studies with an earlier version of the product, which showed an average cure rate of 94%.
Pattern’s pipeline indications include other HPV-associated cancers (5% of all cancers), other cancers caused by viruses (10% of cancers), other cancers caused by infections in general (15% of cancers), and cancers more generally.
Based on existing clinical and pre-clinical data, there are furthermore combination therapy opportunities with conventional cancer therapies and/or other immunotherapies such as checkpoint inhibitors.
The earlier version of the technology has also shown high efficacy against a range of infectious diseases as well as in vaccine applications. P2PAR’s mechanism of action differs from conventional antivirals or other antimicrobials, since it elicits a broad innate immune response.
Collaborations
Pattern has collaborated closely with the Massachusetts General Hospital (Harvard), the National Research Council of Canada (NRC), McGill University (Goodman Cancer Centre and TB Centre), and the University of Toronto.






Pattern is open to partnerships that will move its clinical programs forward and enhance the development of our internal pipeline.
Directors and Leadership
Mark de Groot, PhD
Director and CEO
Hans Keirstead, PhD
Director
Nick Glover, PhD
Director
Andrew Williams, MBA
Chief Financial Officer
Key Advisors and Employees
Ravshan Ataullakhanov, MD, PhD
Clinical and Scientific Advisor
Mark Poznansky, MD, PhD
Clinical and Scientific Advisor
Frank Perabo, MD, PhD
Clinical and Scientific Advisor
Kerry Stirton, MA, LLM
Business Advisor
Elizabeth Acosta, PhD
Director, R&D
Yann Rioux, MSc
Director, Operations
